Cardiomyopathy

74

Pipeline Programs↗

40

Active Trials↗

30

Companies Involved↗

Cardiomyopathy is a moderately active landscape with 74 programs across 30 companies. The most active players are YolTech Therapeutics Co., Ltd, Viking Therapeutics, Inc., Akero Therapeutics. 20 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

22/100

Mech. Concentration

11/100

Completion Rate

75/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

YolTech Therapeutics Co., Ltd

1 program

Viking Therapeutics, Inc.

1 program

Akero Therapeutics

1 program

Pfizer

2 programs

Ionis Pharmaceuticals

1 program

Eidos Therapeutics, a BridgeBio company

1 program

Pipeline

Programs by Phase

Preclinical13

Patisiran

Alnylam Pharmaceuticals

Dexrazoxane Hydrochloride

Children's Oncology Group

Dapagliflozin

AstraZeneca

Losartan

Organon and Co

Empagliflozin

Boehringer Ingelheim

Phase 110

Colchicine

Alnylam Pharmaceuticals

Rosuvastatin

AstraZeneca

Ramipril

Viking Therapeutics, Inc.

Carvedilol

Akero Therapeutics

SGLT2 Inhibitor

Eli Lilly

Phase 217

Mycophenolate Mofetil

Roche

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Spironolactone

Pfizer

Tideglusib

AMO Pharma Limited

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 314

Tafamidis

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Melatonin

Neurim Pharmaceuticals Ltd.

Hydroxychloroquine

Alnylam Pharmaceuticals

Dobutamine

Eli Lilly

Metoprolol Succinate

AstraZeneca

Approved20

Ranolazine

Menarini International Operations Luxembourg SA

Azathioprine

Legacy Health System

Nesiritide

Scios, Inc.

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Aspirin

Bayer

Analysis

Modality Breakdown

86%

Small molecule

68 of 79 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 79 classified programs, each share of the total. Modality classified for 99% of 92 pipeline programs.

Analysis

Trial Status

93

clinical trials

Completed30 · 32%

Recruiting25 · 27%

Unknown status12 · 13%

Active, not recruiting7 · 8%

Terminated6 · 6%

Not yet recruiting5 · 5%

Other8 · 9%

Clinical Trials

Trial Activity

93 trials

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Recruiting·HHamilton Health Sciences Corporation·Phase 2·NCT06174220·120 enrolled

PBMC as Biomarkers of Diabetic Cardiomyopathy

Recruiting·HHospices Civils de Lyon·N/A·NCT05651919·100 enrolled

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT06431919·260 enrolled

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Recruiting· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 3·NCT07052903·1,250 enrolled

Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.

Recruiting·MMedical University of Warsaw·Phase 4·NCT04654988·100 enrolled

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

Recruiting·—·Phase 2·NCT04500665·20 enrolled

Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy

Recruiting·UUniversity of Athens·N/A·NCT06949748·300 enrolled

Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH）

Recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT06352320·500 enrolled

Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy

Recruiting·TTanta University·Phase 3·NCT06846086·46 enrolled

The Effect of Dapagliflozin on Patients With Cardiomyopathy

Recruiting·—·Phase 4·NCT07076615·100 enrolled

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

Recruiting·ZZhejiang University·Phase 1·NCT06082050·7 enrolled

CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Recruiting·NNiguarda Hospital·Phase 3·NCT06158698·80 enrolled

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Recruiting·CCentro Cardiologico Monzino·Phase 2·NCT06922994·102 enrolled

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

Recruiting·WWeill Medical College of Cornell University·Phase 1·NCT05302271·25 enrolled

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02962661·72 enrolled

Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)